U.S. markets open in 8 hours 17 minutes
  • S&P Futures

    4,438.50
    +0.50 (+0.01%)
     
  • Dow Futures

    34,645.00
    +1.00 (+0.00%)
     
  • Nasdaq Futures

    15,287.00
    -16.50 (-0.11%)
     
  • Russell 2000 Futures

    2,256.30
    +1.10 (+0.05%)
     
  • Crude Oil

    73.36
    +0.06 (+0.08%)
     
  • Gold

    1,750.30
    +0.50 (+0.03%)
     
  • Silver

    22.65
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1740
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • Vix

    18.63
    -2.24 (-10.73%)
     
  • GBP/USD

    1.3721
    +0.0001 (+0.01%)
     
  • USD/JPY

    110.4200
    +0.1190 (+0.11%)
     
  • BTC-USD

    44,244.52
    +158.84 (+0.36%)
     
  • CMC Crypto 200

    1,104.81
    -4.12 (-0.37%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    30,223.08
    +583.68 (+1.97%)
     

Evelo Biosciences to Present at 40th Annual Cowen Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 40th Annual Cowen Health Care Conference on Tuesday, March 3rd at 12:00pm EST.

A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.

About Evelo Biosciences
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on SINTAX with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.

Evelo currently has four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact
Evelo Biosciences
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com